Champions Oncology (CSBR) Non-Current Deffered Revenue (2018 - 2019)
Champions Oncology (CSBR) recorded quarterly Non-Current Deffered Revenue of $851000.0 in Q2 2019, up 16.1% quarter-over-quarter from $733000.0 in Q1 2019, and up 87.44% on a YoY basis from $454000.0 in Q2 2018.
Champions Oncology (CSBR) Non-Current Deffered Revenue (2018 - 2019) Analysis & Trends
Champions Oncology's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $851000.0 for Q2 2019.
- In Q2 2019, Non-Current Deffered Revenue rose 87.44% year-over-year to $851000.0; the TTM figure through Apr 2019 stood at $851000.0 (up 87.44% YoY), while the FY2019 annual figure was $851000.0, up 87.44% from the prior year.
- Non-Current Deffered Revenue was $851000.0 for Q2 2019 at Champions Oncology, up from $733000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $851000.0 in Q2 2019 to a low of $454000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Champions Oncology | 82.77 Mn | 75.76 Mn | 13.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2019 | 851,000.00 |
| Jan 31, 2019 | 733,000.00 |
| Oct 31, 2018 | 669,000.00 |
| Jul 31, 2018 | 605,000.00 |
| Apr 30, 2018 | 454,000.00 |